Immunovia to discuss adoption of IMMrayTM PanCan-d with key opinion leaders on May 3, 2023
LUND, SWEDEN – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company that has launched the world’s first test dedicated to the early detection of pancreatic cancer, today announced it will host an event to discuss the adoption of IMMrayTM PanCan-d test key opinion leaders on May 3, 2023, at 16:00 pm CET (10:00 am ET). The event will feature two panel discussions with key opinion leaders: David Bakelman CEO National Pancreas Foundation Cheryl Meguid, DNP Director of the Pancreatic Cancer High Risk Screening Clinic Regional Medical Director of